UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 36

Sortiert nach

Guidelines for the assessment and management of non-alcoholic fatty liver disease in the Asia-Pacific region: Executive summary

Journal of gastroenterology and hepatology, 2007-06, Vol.22 (6), p.775-777

2007

Volltextzugriff (PDF)

Non-alcoholic fatty liver disease in the Asia-Pacific region: Definitions and overview of proposed guidelines

Journal of gastroenterology and hepatology, 2007-06, Vol.22 (6), p.778-787

2007

Volltextzugriff (PDF)

Silver nanoparticles inhibit hepatitis B virus replication

Antiviral therapy, 2008-01, Vol.13 (2), p.253-262

2008

Volltextzugriff (PDF)

Primary biliary cirrhosis-associated hepatocellular carcinoma in Chinese patients:Incidence and risk factors

World journal of gastroenterology : WJG, 2015-03, Vol.21 (12), p.3554-3563

2015

Volltextzugriff (PDF)

Serum hepatitis B surface antigen and hepatitis B e antigen titers: Disease phase influences correlation with viral load and intrahepatic hepatitis B virus markers

Hepatology (Baltimore, Md.), 2010-06, Vol.51 (6), p.1933-1944

2010

Volltextzugriff (PDF)

Asian-Pacific consensus statement on the management of chronic hepatitis B: a 2008 update

Hepatology international, 2008-09, Vol.2 (3), p.263-283

2008

Volltextzugriff (PDF)

Peginterferon Alfa-2a, Lamivudine, and the Combination for HBeAg-Positive Chronic Hepatitis B

The New England journal of medicine, 2005-06, Vol.352 (26), p.2682-2695

2005

Volltextzugriff (PDF)

Peginterferon Alfa-2a Alone, Lamivudine Alone, and the Two in Combination in Patients with HBeAg-Negative Chronic Hepatitis B

The New England journal of medicine, 2004-09, Vol.351 (12), p.1206-1217

2004

Volltextzugriff (PDF)

Hepatitis B e Antigen Seroconversion: A Critical Event in Chronic Hepatitis B Virus Infection

Digestive diseases and sciences, 2010-10, Vol.55 (10), p.2727-2734

2010

Volltextzugriff (PDF)

Therapeutic vaccination of chronic hepatitis B patients with virus suppression by antiviral therapy: A randomized, controlled study of co-administration of HBsAg/AS02 candidate vaccine and lamivudine

Vaccine, 2007-12, Vol.25 (51), p.8585-8597

2007

Volltextzugriff (PDF)

Lansoprazole for the Prevention of Recurrences of Ulcer Complications from Long-Term Low-Dose Aspirin Use

The New England journal of medicine, 2002-06, Vol.346 (26), p.2033-2038

2002

Volltextzugriff (PDF)

Current treatments for patients with HBeAg-positive chronic hepatitis B virus infection: a comparison focusing on HBeAg seroconversion

Liver international, 2010-04, Vol.30 (4), p.512-520

Lau, George K. K.

2010

Volltextzugriff (PDF)

Features of hepatitis C virus infection, current therapies and ongoing clinical trials in ten Asian Pacific countries

Hepatology international, 2015-10, Vol.9 (4), p.486-507

2015

Volltextzugriff (PDF)

Preemptive adefovir versus lamivudine for prevention of hepatitis B reactivation in chronic hepatitis B patients undergoing chemotherapy

Hepatology international, 2015-04, Vol.9 (2), p.224-230

2015

Volltextzugriff (PDF)

HBeAg-positive chronic hepatitis B: why do I treat my patients with pegylated interferon

Liver international, 2009-01, Vol.29 (s1), p.125-129

Lau, George K. K.

2009

Volltextzugriff (PDF)

Asian-Pacific consensus statement on the management of chronic hepatitis B: An update

Journal of gastroenterology and hepatology, 2003-03, Vol.18 (3), p.239-245

2003

Volltextzugriff (PDF)

Fibrosis progression in chronic hepatitis C patients with occult hepatitis B co-infection

Journal of clinical virology, 2006-02, Vol.35 (2), p.185-192

2006

Volltextzugriff (PDF)

Impact of early viral kinetics on T-cell reactivity during antiviral therapy in chronic hepatitis B

Antiviral therapy, 2007-01, Vol.12 (5), p.705-718

2007

Volltextzugriff (PDF)

Clevudine for the treatment of chronic hepatitis B virus infection

Expert opinion on investigational drugs, 2005-10, Vol.14 (10), p.1277-1284

2005

Volltextzugriff (PDF)

Comparison of Real-Time PCR Assays for Monitoring Serum Hepatitis B Virus DNA Levels during Antiviral Therapy

Journal of Clinical Microbiology, 2006-08, Vol.44 (8), p.2983-2987

2006

Volltextzugriff (PDF)

Guidelines for the assessment and management of non‐alcoholic fatty liver disease in the Asia–Pacific region: Executive summary

Journal of gastroenterology and hepatology, 2007-06, Vol.22 (6), p.775-777

2007

Volltextzugriff (PDF)

Use of immunomodulatory therapy (other than interferon) for the treatment of chronic hepatitis B virus infection

Journal of gastroenterology and hepatology, 2000-05, Vol.15 (s2), p.E46-E52

Lau, George Kk

2000

Volltextzugriff (PDF)

Peginterferon-α2a (40 kDa) (Pegasys®) for hepatitis B

Expert review of anti-infective therapy, 2005-08, Vol.3 (4), p.495-504

2005

Volltextzugriff (PDF)

Peginterferon-[alpha]2a (40 kDa) (Pegasys®) for hepatitis B

Expert review of anti-infective therapy, 2005-08, Vol.3 (4), p.495

2005

Volltextzugriff (PDF)

Peginterferon- alpha 2a (40 kDa) (Pegasys registered ) for hepatitis B

Expert review of anti-infective therapy, 2005-08, Vol.3 (4), p.495-504

2005

Volltextzugriff (PDF)

1 – 25 von 36

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(32)
Mit Volltextzugriff
(34)

Publikationsform

Artikel
(35)
Tagungsberichte
(1)

Sprache

Englisch
(36)
Japanisch
(8)

Erscheinungsjahr

n.n

Thema

Science & Technology
(28)
Life Sciences & Biomedicine
(27)
Humans
(26)
Biological And Medical Sciences
(16)
Medical Sciences
(16)
Gastroenterology & Hepatology
(15)
Female
(14)
Male
(14)
Hepatitis B Virus
(13)
Middle Aged
(12)
Infectious Diseases
(11)
Antiviral Agents - Therapeutic Use
(10)
Hepatitis B, Chronic - Drug Therapy
(10)
Human Viral Diseases
(10)
Viral Diseases
(10)
Viral Hepatitis
(10)
Adult
(9)
Aged
(7)
Hepatitis B
(7)
Hepatitis B Virus - Genetics
(7)

15 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Guidelines for the assessment and management of non-alcoholic fatty liver disease in the Asia-Pacific region: Executive summary

Non-alcoholic fatty liver disease in the Asia-Pacific region: Definitions and overview of proposed guidelines

Silver nanoparticles inhibit hepatitis B virus replication

Primary biliary cirrhosis-associated hepatocellular carcinoma in Chinese patients:Incidence and risk factors

Serum hepatitis B surface antigen and hepatitis B e antigen titers: Disease phase influences correlation with viral load and intrahepatic hepatitis B virus markers

Asian-Pacific consensus statement on the management of chronic hepatitis B: a 2008 update

Peginterferon Alfa-2a, Lamivudine, and the Combination for HBeAg-Positive Chronic Hepatitis B

Peginterferon Alfa-2a Alone, Lamivudine Alone, and the Two in Combination in Patients with HBeAg-Negative Chronic Hepatitis B

Hepatitis B e Antigen Seroconversion: A Critical Event in Chronic Hepatitis B Virus Infection

Therapeutic vaccination of chronic hepatitis B patients with virus suppression by antiviral therapy: A randomized, controlled study of co-administration of HBsAg/AS02 candidate vaccine and lamivudine

Lansoprazole for the Prevention of Recurrences of Ulcer Complications from Long-Term Low-Dose Aspirin Use

Current treatments for patients with HBeAg-positive chronic hepatitis B virus infection: a comparison focusing on HBeAg seroconversion

Features of hepatitis C virus infection, current therapies and ongoing clinical trials in ten Asian Pacific countries

Preemptive adefovir versus lamivudine for prevention of hepatitis B reactivation in chronic hepatitis B patients undergoing chemotherapy

HBeAg-positive chronic hepatitis B: why do I treat my patients with pegylated interferon

Asian-Pacific consensus statement on the management of chronic hepatitis B: An update

Fibrosis progression in chronic hepatitis C patients with occult hepatitis B co-infection

Impact of early viral kinetics on T-cell reactivity during antiviral therapy in chronic hepatitis B

Clevudine for the treatment of chronic hepatitis B virus infection

Comparison of Real-Time PCR Assays for Monitoring Serum Hepatitis B Virus DNA Levels during Antiviral Therapy

Guidelines for the assessment and management of non‐alcoholic fatty liver disease in the Asia–Pacific region: Executive summary

Use of immunomodulatory therapy (other than interferon) for the treatment of chronic hepatitis B virus infection

Peginterferon-α2a (40 kDa) (Pegasys®) for hepatitis B

Peginterferon-[alpha]2a (40 kDa) (Pegasys®) for hepatitis B

Peginterferon- alpha 2a (40 kDa) (Pegasys registered ) for hepatitis B

Suchergebnisse filtern